key: cord-0951102-ewo6vvlr
authors: Jha, Sujeet; Batra, Nitish; Siddiqui, Samreen; Yadav, Ashutosh; Misra, Archa; Loomba, Menka; Sethi, Sumeet; Waghdhare, Swati
title: HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers
date: 2020-11-10
journal: Indian Heart J
DOI: 10.1016/j.ihj.2020.11.005
sha: aa2c4dd80325361cd857f02a6d27811e23de8658
doc_id: 951102
cord_uid: ewo6vvlr

BACKGROUND: HCQ is a commonly recommended drug for the prophylaxis of COVID-19. One of its rare side-effect includes QTc prolongation. METHODS: This was a prospective, cross sectional and observational study conducted on Hydroxychloroquine (HCQ) among Healthcare Workers (HCWs) at Max Super Speciality Hospital, Saket, New Delhi, India. A 3-lead ECG (only limb leads, it does not require chest leads) was performed. The QTc cut offs were pre decided, QTC < 470ms for males and < 480ms for females was considered within the normal limits and anything above this was regarded as QTc prolongation. RESULTS: There were 274 HCWs enrolled into the study, including 175 males and 99 females. Majority of the HCWs were young and had a mean age of 32.19±9.29 years. Out of these, 218 were taking HCQ as per the Indian Council of Medical Research (ICMR) guidelines. The median cumulative dose being taken was 1600mg and the median QTc of these participants was 390ms in males and 391.5ms in females. Subsequently, 33 participants were followed-up and found to have a median QTc of 389ms and a cumulative dose of HCQ as 2000mg. CONCLUSION: In conclusion, ours is a first study in the middle of the pandemic which showed that HCQ prophylaxis in young HCWs without comorbidities did not show any QTc prolongation.

In the current era of rapidly rising cases of coronavirus illness 2019 (Covid-19) infection, multiple treatment and prophylaxis options have been tried with various degrees of success rates as well as accompanying side effects. HCQ is one of the commonly recommended medications for the population at high-risk of exposure, as it has both anti-inflammatory and antiviral effects. (1, 2, 3, 4, 5, 6, 7) The Indian Council for Medical Research (ICMR), National Task Force for COVID 19 issued recommendations for HCQ to be used as a prophylaxis for the asymptomatic exposed Healthcare Workers (HCW) in late March 2020. (8) Since these and similar recommendations have come up, several questions have been raised in regards to its cardiac toxicity particularly QTc prolongation. HCQ is recommended as a prophylaxis as it is a long acting drug with a terminal halflife of more than 40 days. (9) There is a high-risk of side-effects on cumulative dosing. The most common side effects of HCQ include gastrointestinal symptoms, pruritus, hypoglycaemia, retinopathy, neuropsychiatric effects and dermatological changes that can occur in up to 10% of the patients. (10, 11) The most severe side effects have low incidence, which includes neuromyopathy of proximal muscles, cardiotoxicity, and irreversible retinopathy. A rarer side effect of HCQ is prolonged QTc interval leading to arrhythmias and on rare occasions, life threatening arrhythmia Torsades-de-pointes (Tdp). Even though occurrence of Tdp is very uncommon, the risk is increased in patients receiving medications that have an additive effect of prolonged QTc, such as anti-infective drugs (Macrolides, Azole anti fungals, Bedaquiline, Lopinavir, and Ritonavir, etc.), psychotropic drugs (Chlorpromazine, Haloperidol, etc.), Ondansetron, Formetrol, etc. (12) However majority of these side effects have been studied in treatment doses but none in prophylactic doses. Essentially all the drugs that create LQTS (Long QT syndrome) act by blocking the rapid delayed rectifier channel (IKr) current interceded by the potassium channel encoded by the KCNH2 quality. (13) We decided to proceed quickly to understand QTc prolongation due to HCQ as large work force in our institution was recommended HCQ for prophylaxis as per the ICMR guidelines.

This was a prospective, cross sectional and observational study conducted on HCQ among HCWs at Max Super Speciality Hospital, Saket, New Delhi, India. The Institutional Ethics Committee approved the study. We enrolled Healthcare workers (HCW) coming to the hospital.

The inclusion criteria were HCWs, > 18 years of age and consenting to participate. The QTc cut offs were pre decided, QTC < 470ms for males and < 480ms for females was considered within the normal limits and anything above this was regarded as QTc prolongation. (13) A process was set up to meet the cardiologist if the QTc was prolonged.

We decided to follow up a subset of the study population to see the effects of cumulative doses of HCQ on those HCWs who continued to take it. The follow-up was done on 33 participants and a repeat ECG was recorded after an interval of one-month of their baseline ECG.

We enrolled 274 HCWs out of which 218 were taking HCQ prophylaxis as per the guidelines.

The mean age of participants was 32.28±9.29 years. The demographics of the participants is shown in the table 1.

None of the study participant was found to have COVID-19 during the study period. However during this period the hospital prevalence was also low (1.8%). (14) The HCWs were at different doses of prophylaxis at this cross-section of time.

Majority of participants were on HCQ and they had taken it as per ICMR guidelines i.e. a dose of 400 mg twice a day for 1 day only, followed by 400 mg once a week for 7 weeks. Of the 218 who were on HCQ, 138 (63.3%) were males and 80 (36.6 %) were females. Mean age of these participants was 32.19±9.29 years. Maximum number of participants had taken it upto 3 weeks.

The median dose taken by participants was 1600 mg. The median QTc was 390ms in males and 391.5ms in females. Figure 1 shows the distribution of participants in different QTc ranges. We did not have any participants having any structural/congenital heart disease and none of them 

The present study was aimed to find any effect of HCQ prophylaxis on QTc prolongation amongst the HCWs. We found that majority of the HCWs were young (32.19±9.29 years) and had no co-morbidities.

At the time of this study, the cumulative dose taken by most of the participants was 1600mg over 3 weeks' time. We did not observe any QTc prolongation in any of the participants. As the pandemic and its prophylaxis continued, we followed-up 33 participants with ECG and found the cumulative dose of 2000mg as the median. Interestingly, there was no QTc prolongation at this dose also. Ever since the ICMR recommendations for HCQ use as prophylaxis for asymptomatic HCWs has come, many concerns regarding its association with QTc prolongation have been raised.

However, we did not come across any such findings. Some studies done by ICMR (15) and Closon et al (16) concluded that in this era of Sars-Cov-19, HCQ provided significant advantage as a part of treatment/prophylaxis for the same, even though there would be more studies required with larger number of subjects to come to a definite conclusion. (17) J o u r n a l P r e -p r o o f This is the first study on prophylaxis and QTc prolongation, in contrast to a study in Nature

Medicine showing QTc prolongation in 9 patients who were on treatment (HCQ+ Azithromycin). (18) With this study, our purpose was neither to recommend nor discourage the use of HCQ as a prophylaxis.

Ours is a first study in the middle of the pandemic which showed that HCQ prophylaxis in young HCWs without comorbidities did not show any QTc prolongation. However large population based studies would further validate our results. Randomised control studies are being conducted worldwide to determine the safety and efficacy of HCQ as prophylaxis in COVID-19.

The sample size was small, however it was well representative of the HCWs population. The follow up of the patients need to be done further upto at least 7 weeks.

There are no conflicts of interest involved in this study J o u r n a l P r e -p r o o f 

New insights into the antiviral effects of chloroquine. The Lancet Infectious Diseases

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Of chloroquine and COVID-19

Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment? Clinical Infectious Diseases

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-COV-2 infection. MOHFW; 2020

Bioavailability of hydroxychloroquine tablets in healthy volunteers

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

Hydroxychloroquine and covid-19

Prevalence of Flu-like Symptoms and COVID-19 in Healthcare Workers from India

Advisory on the use of hydroxy-chloroquine as prophylaxis for SARS-CoV-2 infection

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19

A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19)

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin

J o u r n a l P r e -p r o o f